Most Popular
-
1
Tensions heighten ahead of first president-opposition chief meeting
-
2
Seoul to provide housing subsidy to married couples with newborns
-
3
[KH Explains] No more 'Michael' at Kakao Games
![[KH Explains] No more 'Michael' at Kakao Games](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/28/20240428050183_0.jpg&u=20240428180321)
-
4
Rapper jailed after public street fight with another rapper
-
5
Woman gets suspended term for injuring boyfriend with knife
![[KH Explains] No more 'Michael' at Kakao Games](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/28/20240428050183_0.jpg&u=20240428180321)
-
6
Samsung chief bolsters ties with Germany’s Zeiss
-
7
NewJeans pops out ‘Bubble Gum’ video amid troubles at agency
-
8
Nominee for chief of anti-corruption body pledges 'independence, effectiveness'
-
9
Med schools expect 1,500+ new admission slots next year
-
10
KT launches new mobile plans for foreign residents
SK Biopharm, Hanmi sign deal to sell epilepsy drug
By Korea HeraldPublished : April 22, 2012 - 21:09
SK Biopharmaceuticals Co. said Sunday it established a strategic partnership with Hanmi Pharm Co. to sell a nasal spray-type epilepsy drug in Korea and China.
Hanmi and its Chinese arm will get the approval for sales and handle marketing in Korea and China, under the partnership.
The diazepam nasal spray quickly transfers the diazepam substance to the brain through the mucous membranes inside the nasal cavity, allowing swift treatment, according to SK Biopharm.
The pharmaceutical company expects to commercialize the drug in Korea next year and in China in 2015.
SK Biopharm plans to file for approval on the new drug sales through its U.S. importer to the U.S. Food and Drug Administration in the first half of this year after completing clinical trials.
(sophie@heraldcorp.com)
Hanmi and its Chinese arm will get the approval for sales and handle marketing in Korea and China, under the partnership.
The diazepam nasal spray quickly transfers the diazepam substance to the brain through the mucous membranes inside the nasal cavity, allowing swift treatment, according to SK Biopharm.
The pharmaceutical company expects to commercialize the drug in Korea next year and in China in 2015.
SK Biopharm plans to file for approval on the new drug sales through its U.S. importer to the U.S. Food and Drug Administration in the first half of this year after completing clinical trials.
(sophie@heraldcorp.com)
-
Articles by Korea Herald
![[Herald Interview] Mistakes turn into blessings in street performance, director says](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=652&simg=/content/image/2024/04/28/20240428050150_0.jpg&u=20240428174656)
